These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1501383)
1. Some aspects in treatment of superficial bladder cancer. Alfthan O Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):802. PubMed ID: 1501383 [No Abstract] [Full Text] [Related]
2. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands. Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587 [No Abstract] [Full Text] [Related]
3. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related]
4. Bacillus Calmette-Guérin immunotherapy. Techniques and results. Brosman SA Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239 [TBL] [Abstract][Full Text] [Related]
6. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ. Brosman S Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993 [No Abstract] [Full Text] [Related]
7. Bladder carcinoma--the good, the bad and the ugly. Manyak MJ J Urol; 1996 Jan; 155(1):103-4. PubMed ID: 7490802 [No Abstract] [Full Text] [Related]
8. BCG for bladder cancer. Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783 [No Abstract] [Full Text] [Related]
9. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. Pisters LL; Tykochinsky G; Wajsman Z J Urol; 1991 Dec; 146(6):1514-7. PubMed ID: 1942330 [TBL] [Abstract][Full Text] [Related]
10. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer. Brosman SA; Lamm DL J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197 [TBL] [Abstract][Full Text] [Related]
11. BCG in management of superficial bladder cancer. Guinan P; Crispen R; Rubenstein M Urology; 1987 Dec; 30(6):515-9. PubMed ID: 3318088 [TBL] [Abstract][Full Text] [Related]
12. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group. Bouffioux C Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428 [No Abstract] [Full Text] [Related]
13. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]
14. Management of superficial transitional cell carcinoma of the bladder. Fleischmann J; Goldberg G Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825 [TBL] [Abstract][Full Text] [Related]
15. BCG in superficial bladder cancer: a review of phase III European trials. Pagano F; Bassi P; Milani C; Piazza N; Meneghini A; Garbeglio A Eur Urol; 1992; 21 Suppl 2():7-11. PubMed ID: 1396947 [TBL] [Abstract][Full Text] [Related]
16. [Intravesical Calmette-Guérin bacillus therapy of bladder tumors]. Uchida T; Muruyama M; Igarashi M; Kobayashi K; Mashimo S; Ishibashi A; Koshiba K; Shibuya M Nihon Hinyokika Gakkai Zasshi; 1987 Dec; 78(12):2087-97. PubMed ID: 3451983 [No Abstract] [Full Text] [Related]